Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 106

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 6
Chunk 106
---

Anthony Pagano                           ​    47   ​   Executive Vice President and Chief Financial Officer                              
Judith Klimovsky                         ​    68   ​   Executive Vice President and Chief Development Officer                            
Tahamtan Ahmadi                          ​    52   ​   Executive Vice President and Chief Medical Officer, Head of Experimental Medicines
Birgitte Stephensen                      ​    64   ​   Executive Vice President and Chief Legal Officer                                  
Christopher Cozic                        ​    47   ​   Executive Vice President and Chief People Officer                                 
Martine J. van Vugt                      ​    54   ​   Executive Vice President and Chief Strategy Officer                               
Rayne Waller*                            ​     ​   ​   Executive Vice President and Chief Technical Operations Officer                   
Brad Bailey*                             ​    57   ​   Executive Vice President and Chief Commercial Officer                             
* – Brad Bailey and Rayne Waller were appointed Executive Vice President and Chief Commercial Officer, and Executive Vice President and Chief Technical Operations Officer, respectively, and members of the Executive Management in August 2024.

84

​
The following is a brief summary of the business experience of our Executive Management.
Jan G. J. van de Winkel is our co-founder and served as President, Research & Development and Chief Scientific Officer of the Company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel served as Vice President and Scientific Director of Medarex Europe prior to founding Genmab. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He holds an M.Sc. and a Ph.D. from the Radboud University of Nijmegen in the Netherlands.
Anthony Pagano joined Genmab in 2007. His positions increased in seniority during his tenure with us and he currently serves as our Executive Vice President and Chief Financial Officer. Prior to joining us, Mr. Pagano was Corporate Controller and Senior Director of Business Planning at NovaDel Pharma, Inc. from 2005 to 2007, a publicly-traded specialty pharmaceutical company. He previously worked as a Manager at KPMG LLP from 1999 to 2005. He is a CPA and received a B.S. in Accounting from The College of New Jersey, as well as an MBA from the Stern School of Business at New York University.
Judith Klimovsky joined us in 2017 and currently serves as the Executive Vice President and Chief Development Officer. She worked previously